:@0.085519:0.075583:0.090751:0.075583:0.090751:0.059604:0.085519:0.059604:0.005232
 :@0.621674:0.075583:0.626906:0.075583:0.626906:0.059604:0.621674:0.059604:0.005232
 :@0.884977:0.940183:0.890322:0.940183:0.890322:0.922163:0.884977:0.922163:0.005345
Oral Presenter Abstract :@0.736982:0.075583:0.918858:0.075583:0.918858:0.059604:0.736982:0.059604:0.011658:0.006331:0.008492:0.004000:0.005293:0.010369:0.006331:0.008929:0.008569:0.008929:0.009573:0.005251:0.008929:0.006382:0.005321:0.010407:0.009403:0.008511:0.005289:0.006275:0.008531:0.008531:0.005340:0.005232
OD-7 :@0.083238:0.078923:0.146583:0.078923:0.146583:0.060156:0.083238:0.060156:0.018529:0.017104:0.007982:0.013113:0.006617
Knockdown of OTUB1 and OTUB2 Induces Cell Cycle Arrest and Modulates :@0.103478:0.158311:0.902407:0.158311:0.902407:0.136326:0.103478:0.136326:0.014528:0.013355:0.013146:0.011816:0.011842:0.013537:0.013042:0.017424:0.013407:0.006521:0.013120:0.007381:0.006521:0.016119:0.013042:0.016145:0.014580:0.013042:0.006521:0.012650:0.013355:0.013537:0.006417:0.016041:0.013146:0.016041:0.014580:0.013120:0.006521:0.007434:0.013355:0.013537:0.013407:0.011685:0.013068:0.011842:0.006521:0.014294:0.013068:0.006756:0.006651:0.006573:0.014294:0.011685:0.011816:0.006651:0.013068:0.006599:0.014372:0.008686:0.008686:0.013120:0.011842:0.007668:0.006521:0.012703:0.013355:0.013537:0.006573:0.020475:0.013146:0.013537:0.013355:0.006729:0.012650:0.007668:0.013146:0.011842:0.006521
Cancer Regulatory Gene Expression in Hepatocellular Carcinoma Cells :@0.125000:0.182399:0.881663:0.182399:0.881663:0.160414:0.125000:0.160414:0.014294:0.012650:0.013355:0.011816:0.013146:0.008686:0.006521:0.015415:0.013068:0.013589:0.013355:0.006703:0.012650:0.007668:0.013146:0.008686:0.011685:0.006521:0.016119:0.013068:0.013407:0.013068:0.006573:0.012963:0.011685:0.013537:0.008686:0.013068:0.011842:0.011842:0.006703:0.013042:0.013433:0.006521:0.006703:0.013355:0.006521:0.016067:0.013068:0.013537:0.012650:0.007721:0.013042:0.011868:0.013068:0.006729:0.006651:0.013407:0.006547:0.012650:0.008686:0.006573:0.014294:0.012650:0.008686:0.011816:0.006651:0.013433:0.013042:0.019719:0.012650:0.006521:0.014294:0.013068:0.006756:0.006651:0.012561:0.006521
Wu Yanming and Nurulisa Zulkifle*:@0.335851:0.224794:0.664218:0.224794:0.664218:0.204731:0.335851:0.204731:0.018923:0.011973:0.006403:0.013187:0.010664:0.011925:0.018447:0.004951:0.011925:0.011899:0.006556:0.010545:0.011925:0.011997:0.006403:0.014662:0.011925:0.007950:0.011925:0.004856:0.004951:0.010687:0.010664:0.006474:0.011925:0.011925:0.004808:0.010592:0.004951:0.006689:0.004951:0.011283:0.009426
 :@0.664149:0.224434:0.670049:0.224434:0.670049:0.206413:0.664149:0.206413:0.005901
Department of Biomedical Sciences, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Bertam, :@0.086089:0.264748:0.918764:0.264748:0.918764:0.246728:0.086089:0.246728:0.011780:0.008766:0.009578:0.008231:0.006072:0.004725:0.014367:0.008766:0.009514:0.004661:0.005430:0.009578:0.004682:0.005259:0.010626:0.004276:0.009578:0.014410:0.008702:0.009578:0.004276:0.008295:0.008231:0.004276:0.005345:0.010690:0.008295:0.004276:0.008766:0.009493:0.008381:0.008702:0.008253:0.004682:0.005430:0.010690:0.009578:0.008231:0.008231:0.009621:0.008295:0.008637:0.009578:0.005345:0.015308:0.008766:0.009578:0.004276:0.008295:0.008231:0.004276:0.005430:0.008231:0.009621:0.009514:0.005388:0.011780:0.008766:0.009535:0.004661:0.008295:0.004276:0.005388:0.004789:0.009621:0.008253:0.004661:0.004276:0.004725:0.009599:0.004661:0.008552:0.004682:0.005409:0.011802:0.009621:0.004276:0.008231:0.008680:0.006072:0.008295:0.004276:0.004661:0.004169:0.005388:0.010690:0.008231:0.004276:0.009621:0.008253:0.005259:0.015308:0.008231:0.004276:0.008231:0.008274:0.008253:0.004276:0.008231:0.004746:0.005388:0.010626:0.008766:0.005986:0.004661:0.008295:0.014367:0.004597:0.005345
13200 Kepala Batas, Penang, Malaysia:@0.355093:0.283091:0.644767:0.283091:0.644767:0.265071:0.355093:0.265071:0.009578:0.009578:0.009493:0.009578:0.009578:0.005345:0.010604:0.008659:0.009578:0.008231:0.004276:0.008231:0.005430:0.010626:0.008317:0.004661:0.008231:0.008253:0.004682:0.005345:0.010711:0.008702:0.009557:0.008231:0.009621:0.009557:0.004682:0.005345:0.015308:0.008231:0.004276:0.008274:0.008274:0.008253:0.004148:0.008231
 :@0.644907:0.283451:0.650858:0.283451:0.650858:0.263388:0.644907:0.263388:0.005951
*Corresponding Author: nurulisa@usm.my :@0.338559:0.321491:0.666785:0.321491:0.666785:0.303470:0.338559:0.303470:0.008188:0.011823:0.009493:0.006072:0.006157:0.008702:0.008253:0.009578:0.009578:0.009514:0.009578:0.004361:0.009557:0.009557:0.005345:0.010733:0.009607:0.004661:0.009621:0.009578:0.006072:0.004682:0.005409:0.009557:0.009599:0.006072:0.009599:0.004276:0.004276:0.008253:0.008231:0.017147:0.009514:0.008381:0.014367:0.004682:0.014431:0.008378:0.005345
Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide, ranking :@0.171085:0.361964:0.920514:0.361964:0.920514:0.341901:0.171085:0.341901:0.013139:0.009664:0.010664:0.009164:0.005118:0.010664:0.009236:0.009759:0.004761:0.004642:0.010687:0.004761:0.009164:0.006760:0.005689:0.009236:0.009164:0.006689:0.009236:0.004761:0.010711:0.010664:0.015995:0.009069:0.005713:0.006689:0.013139:0.013163:0.013044:0.006689:0.005713:0.004761:0.009069:0.005713:0.009164:0.005665:0.004761:0.009640:0.009164:0.010664:0.004689:0.010711:0.010640:0.005594:0.009236:0.009164:0.010687:0.009188:0.009759:0.005546:0.010664:0.005213:0.005641:0.009236:0.009164:0.010711:0.009236:0.009688:0.006760:0.005641:0.015995:0.010664:0.006760:0.005070:0.009164:0.004665:0.004761:0.005189:0.009259:0.005713:0.013258:0.010664:0.006760:0.004665:0.010664:0.013377:0.004761:0.010664:0.009759:0.005070:0.005713:0.006760:0.009069:0.010711:0.009164:0.004642:0.010711:0.010521:0.005951
among  the  top  six  cancers  globally.  Despite  advances  in  molecular  markers,  HCC  remains :@0.085519:0.385346:0.920090:0.385346:0.920090:0.365283:0.085519:0.365283:0.009164:0.015924:0.010664:0.010711:0.010640:0.005951:0.006474:0.005189:0.010640:0.009759:0.005951:0.006355:0.005189:0.010664:0.010664:0.005951:0.006427:0.009236:0.004761:0.009474:0.005951:0.006450:0.009236:0.009164:0.010711:0.009236:0.009688:0.006760:0.009188:0.005951:0.006308:0.010640:0.004761:0.010664:0.010664:0.009164:0.004761:0.004642:0.009212:0.005308:0.005951:0.006427:0.013115:0.009759:0.009188:0.010664:0.004761:0.005118:0.009759:0.005951:0.006355:0.009164:0.010664:0.009164:0.009069:0.010711:0.009236:0.009759:0.009188:0.005951:0.006450:0.004761:0.010640:0.005951:0.006427:0.015995:0.010664:0.004761:0.009640:0.009236:0.010687:0.004761:0.009164:0.006641:0.005951:0.006427:0.015995:0.009164:0.006760:0.009164:0.009664:0.006760:0.009188:0.005260:0.005951:0.006427:0.013139:0.013092:0.013163:0.005951:0.006379:0.006760:0.009640:0.016091:0.009164:0.004665:0.010711:0.009188:0.005951
challenging to treat, necessitating ongoing research into novel therapeutic targets. Deubiquitinating :@0.085519:0.408762:0.920466:0.408762:0.920466:0.388699:0.085519:0.388699:0.009236:0.010711:0.009164:0.004665:0.004761:0.009640:0.010711:0.010640:0.004761:0.010711:0.010640:0.006379:0.005189:0.010664:0.006355:0.005189:0.006641:0.009759:0.009045:0.005189:0.005213:0.006403:0.010711:0.009664:0.009236:0.009759:0.009188:0.009283:0.004761:0.005070:0.009164:0.005094:0.004761:0.010640:0.010640:0.006308:0.010664:0.010711:0.010640:0.010711:0.004761:0.010640:0.010545:0.006379:0.006760:0.009640:0.009236:0.009759:0.009045:0.006760:0.009236:0.010711:0.006331:0.004761:0.010640:0.005189:0.010664:0.006355:0.010711:0.010664:0.009164:0.009664:0.004761:0.006331:0.005189:0.010640:0.009759:0.006641:0.009164:0.010664:0.009688:0.010687:0.005189:0.004642:0.009236:0.006427:0.005189:0.009069:0.006760:0.010991:0.009759:0.005070:0.009236:0.005213:0.006450:0.013115:0.009759:0.010687:0.010664:0.004665:0.010664:0.010687:0.004761:0.005094:0.004761:0.010640:0.009164:0.005094:0.004761:0.010640:0.010806:0.005951
enzymes (DUBs) such as OTUB1 and OTUB2 are implicated in these processes and are found to be :@0.085519:0.432144:0.920233:0.432144:0.920233:0.412082:0.085519:0.412082:0.009759:0.010616:0.008069:0.009307:0.015995:0.009664:0.009188:0.005951:0.006689:0.013115:0.013139:0.011640:0.009236:0.006546:0.005855:0.009236:0.010687:0.009236:0.010568:0.005951:0.009164:0.009117:0.005951:0.012996:0.010640:0.013139:0.011830:0.010568:0.005951:0.009021:0.010711:0.010664:0.005951:0.013020:0.010640:0.013139:0.011830:0.010568:0.005951:0.009164:0.006760:0.009616:0.005951:0.004761:0.015805:0.010664:0.004761:0.004665:0.009236:0.009164:0.005189:0.009616:0.010664:0.005951:0.004761:0.010711:0.005951:0.005189:0.010711:0.009640:0.009236:0.009759:0.005784:0.010664:0.006760:0.010664:0.009236:0.009759:0.009069:0.009236:0.009759:0.009045:0.005951:0.009164:0.010711:0.010521:0.005951:0.009164:0.006760:0.009616:0.005951:0.005284:0.010545:0.010687:0.010711:0.010521:0.005951:0.005189:0.010521:0.005951:0.010664:0.009759:0.005951
upregulated in HCC. This study aims to investigate the effects of OTUB1 and OTUB2 knockdown on :@0.085519:0.455527:0.920424:0.455527:0.920424:0.435464:0.085519:0.435464:0.010687:0.010664:0.006760:0.009664:0.010640:0.010687:0.004761:0.009164:0.005094:0.009759:0.010664:0.005808:0.004761:0.010640:0.005855:0.013234:0.013163:0.013068:0.005213:0.005951:0.010640:0.010711:0.004689:0.009236:0.005855:0.009236:0.005189:0.010497:0.010664:0.009259:0.005855:0.009164:0.004665:0.015995:0.009188:0.005951:0.005070:0.010664:0.005879:0.004761:0.010640:0.009164:0.009640:0.009236:0.005189:0.004642:0.010640:0.009164:0.005189:0.009759:0.005879:0.005189:0.010640:0.009759:0.005784:0.009759:0.005213:0.005213:0.009759:0.009236:0.005189:0.009188:0.005951:0.010664:0.005213:0.005855:0.012972:0.010545:0.013139:0.011830:0.010664:0.005855:0.009164:0.010711:0.010664:0.005808:0.013139:0.010640:0.013139:0.011830:0.010664:0.005736:0.009164:0.010711:0.010664:0.009236:0.009164:0.010664:0.010664:0.013377:0.010711:0.005713:0.010664:0.010568:0.005951
cell cycle progression and gene expression in HCC cells to evaluate their potential as therapeutic :@0.085519:0.478909:0.920315:0.478909:0.920315:0.458846:0.085519:0.458846:0.009236:0.009759:0.004665:0.004761:0.007331:0.009236:0.009259:0.009236:0.004761:0.009664:0.007379:0.010664:0.006760:0.010664:0.010640:0.006760:0.009521:0.009236:0.009236:0.004761:0.010664:0.010521:0.007379:0.009164:0.010711:0.010664:0.007212:0.010640:0.009759:0.010711:0.009664:0.007379:0.009759:0.009474:0.010664:0.006760:0.009664:0.009236:0.009236:0.004761:0.010664:0.010521:0.007379:0.004761:0.010640:0.007770:0.012972:0.013163:0.013068:0.007379:0.009236:0.009759:0.004665:0.004761:0.009188:0.007403:0.005189:0.010664:0.007355:0.009759:0.009045:0.009164:0.004665:0.010806:0.009164:0.005094:0.009759:0.007331:0.005189:0.010640:0.009759:0.004761:0.006760:0.007355:0.010664:0.010664:0.005189:0.009688:0.010711:0.005118:0.004761:0.009164:0.004761:0.007379:0.009164:0.009188:0.007426:0.005189:0.010640:0.009759:0.006641:0.009164:0.010664:0.009688:0.010687:0.005189:0.004642:0.009378:0.005951
targets. To achieve this, HepG2:@0.085519:0.502191:0.349539:0.502191:0.349539:0.482128:0.085519:0.482128:0.005189:0.009069:0.006760:0.010640:0.009688:0.005189:0.009188:0.005260:0.006808:0.010640:0.010711:0.006808:0.009164:0.009236:0.010711:0.004665:0.009545:0.009164:0.009640:0.006808:0.005189:0.010640:0.004761:0.009188:0.005260:0.006808:0.013139:0.009664:0.010664:0.013163:0.010664
KRAB:@0.349819:0.494927:0.378269:0.494927:0.378269:0.482913:0.349819:0.482913:0.007112:0.007127:0.007127:0.007084
 stable cells were transfected with CRISPR guide RNA plasmids :@0.378326:0.502191:0.920181:0.502191:0.920181:0.482128:0.378326:0.482128:0.006842:0.009236:0.005189:0.009069:0.010664:0.004761:0.009664:0.006808:0.009236:0.009759:0.004665:0.004761:0.009188:0.006831:0.013377:0.009759:0.006641:0.009759:0.006760:0.005189:0.006641:0.009164:0.010711:0.009188:0.005260:0.009759:0.009236:0.005094:0.009759:0.010664:0.006784:0.013377:0.004761:0.005189:0.010711:0.006855:0.013163:0.012068:0.005332:0.011901:0.011830:0.012163:0.006784:0.010640:0.010687:0.004761:0.010664:0.009759:0.006641:0.012163:0.013068:0.011901:0.006879:0.010664:0.004761:0.009093:0.009236:0.015995:0.004665:0.010545:0.009236:0.005951
targeting OTUB1 and OTUB2 using Lipofectamine. Subsequently, Cell cycle analysis was conducted :@0.085519:0.525573:0.920424:0.525573:0.920424:0.505510:0.085519:0.505510:0.005189:0.009069:0.006760:0.010640:0.009688:0.005189:0.004642:0.010711:0.010640:0.005736:0.013139:0.010640:0.013139:0.011830:0.010664:0.005736:0.009164:0.010711:0.010664:0.005665:0.013139:0.010640:0.013139:0.011830:0.010664:0.005736:0.010545:0.009236:0.004761:0.010640:0.010640:0.005760:0.010545:0.004761:0.010664:0.010664:0.005213:0.009616:0.009236:0.005189:0.009164:0.015900:0.004761:0.010640:0.009759:0.005213:0.005689:0.011901:0.010735:0.010545:0.009236:0.009759:0.010664:0.010687:0.009664:0.010711:0.005118:0.004761:0.009212:0.005213:0.005760:0.012972:0.009759:0.004642:0.004761:0.005641:0.009236:0.009259:0.009236:0.004761:0.009664:0.005713:0.009164:0.010711:0.009069:0.004761:0.009212:0.009236:0.004761:0.009188:0.005713:0.013377:0.009164:0.009188:0.005760:0.009236:0.010664:0.010592:0.010664:0.010687:0.009236:0.005189:0.009759:0.010664:0.005951
using  Propidium  Iodide  (PI)  staining.  Furthermore,  RT-PCR  was  performed  using  primers  for :@0.085519:0.548956:0.920327:0.548956:0.920327:0.528893:0.085519:0.528893:0.010687:0.009236:0.004761:0.010640:0.010640:0.005951:0.004761:0.011830:0.006760:0.010497:0.010664:0.004761:0.010664:0.004761:0.010687:0.015900:0.005951:0.004713:0.005332:0.010664:0.010664:0.004761:0.010664:0.009664:0.005951:0.004713:0.006689:0.011830:0.005332:0.006689:0.005951:0.004689:0.009236:0.005189:0.009069:0.004761:0.010640:0.004761:0.010640:0.010640:0.005308:0.005951:0.004713:0.010664:0.010687:0.006760:0.005094:0.010711:0.009664:0.006760:0.015900:0.010664:0.006760:0.009664:0.005213:0.005951:0.004784:0.012163:0.010916:0.007982:0.011830:0.013163:0.012068:0.005951:0.004713:0.013377:0.009164:0.009093:0.005951:0.004713:0.010664:0.009759:0.006665:0.005213:0.010735:0.006760:0.015900:0.009759:0.010664:0.005951:0.004665:0.010687:0.009236:0.004761:0.010497:0.010640:0.005951:0.004761:0.010664:0.006760:0.004665:0.015995:0.009664:0.006760:0.009188:0.005951:0.004737:0.005213:0.010735:0.006546:0.005951
selected cancer-related genes, including :@0.085519:0.572338:0.433927:0.572338:0.433927:0.552275:0.085519:0.552275:0.009236:0.009759:0.004642:0.009759:0.009236:0.005094:0.009759:0.010664:0.008012:0.009236:0.009164:0.010711:0.009236:0.009688:0.006698:0.007982:0.006760:0.009640:0.004761:0.009069:0.005189:0.009640:0.010664:0.007974:0.010640:0.009759:0.010711:0.009664:0.009236:0.005213:0.008021:0.004761:0.010640:0.009117:0.004761:0.010687:0.010664:0.004665:0.010711:0.010640:0.005951
c-Myc, TP53, HIF-:@0.436051:0.572338:0.595702:0.572338:0.595702:0.552275:0.436051:0.552275:0.009265:0.007839:0.016971:0.009212:0.009283:0.005141:0.007950:0.010545:0.011830:0.010664:0.010664:0.005213:0.007926:0.013139:0.005237:0.010823:0.007950
1α, VEGF, Bcl:@0.595591:0.572338:0.715700:0.572338:0.715700:0.552275:0.595591:0.552275:0.010664:0.011140:0.005213:0.007879:0.011901:0.010664:0.013068:0.010664:0.005284:0.007950:0.011687:0.009236:0.004761
-2, NF-:@0.715745:0.572338:0.779140:0.572338:0.779140:0.552275:0.715745:0.552275:0.007982:0.010545:0.005213:0.008021:0.013139:0.010545:0.007950
κB, and CDH:@0.779171:0.572338:0.890925:0.572338:0.890925:0.552275:0.779171:0.552275:0.008974:0.011830:0.005213:0.008021:0.009164:0.010711:0.010473:0.007950:0.013163:0.013115:0.013139
-1.:@0.890964:0.572338:0.914705:0.572338:0.914705:0.552275:0.890964:0.552275:0.007982:0.010547:0.005213
 :@0.914624:0.572338:0.920574:0.572338:0.920574:0.552275:0.914624:0.552275:0.005951
Finally, Statistical analyses were conducted using SPSS with significance set at p<0.05. As a result, :@0.085519:0.595720:0.919948:0.595720:0.919948:0.575657:0.085519:0.575657:0.010664:0.004761:0.010711:0.009069:0.004761:0.004642:0.009212:0.005308:0.006093:0.011901:0.005189:0.009164:0.005094:0.004761:0.009188:0.005189:0.004665:0.009236:0.009164:0.004761:0.006046:0.009164:0.010711:0.009069:0.004761:0.009212:0.009236:0.009759:0.009188:0.005951:0.013377:0.009759:0.006760:0.009640:0.006093:0.009236:0.010664:0.010711:0.010664:0.010687:0.009307:0.005189:0.009640:0.010664:0.006141:0.010545:0.009236:0.004761:0.010640:0.010640:0.006022:0.011901:0.011878:0.011901:0.011901:0.005951:0.013377:0.004761:0.005189:0.010640:0.006093:0.009236:0.004761:0.010640:0.010711:0.004665:0.005213:0.004618:0.009236:0.009164:0.010711:0.009236:0.009688:0.006093:0.009236:0.009759:0.005070:0.006093:0.009164:0.005094:0.006093:0.010664:0.010664:0.010664:0.005070:0.010664:0.010664:0.005213:0.006070:0.011901:0.009188:0.006117:0.009164:0.006070:0.006760:0.009640:0.009236:0.010687:0.004761:0.005070:0.005141:0.005951
PI staining shows a significant increase in the proportion of HepG2:@0.085519:0.619002:0.637052:0.619002:0.637052:0.598939:0.085519:0.598939:0.011830:0.005332:0.005213:0.009236:0.005189:0.009069:0.004761:0.010640:0.004761:0.010640:0.010640:0.005332:0.009236:0.010711:0.010521:0.013377:0.009188:0.005237:0.009164:0.005237:0.009236:0.004761:0.010640:0.010711:0.004665:0.005213:0.004761:0.009236:0.009164:0.010711:0.005094:0.005284:0.004761:0.010640:0.009236:0.006593:0.009759:0.009045:0.009236:0.009759:0.005213:0.004761:0.010640:0.005284:0.005189:0.010640:0.009759:0.005213:0.010664:0.006760:0.010664:0.010664:0.010568:0.006760:0.005070:0.004761:0.010664:0.010711:0.005213:0.010664:0.005284:0.005284:0.013139:0.009664:0.010664:0.013163:0.010664
KRAB/OTUB1:@0.637210:0.611738:0.705283:0.611738:0.705283:0.599725:0.637210:0.599725:0.007112:0.007283:0.006984:0.007084:0.004005:0.007868:0.006400:0.007868:0.007084:0.006385
 and HepG2:@0.705340:0.619002:0.803683:0.619002:0.803683:0.598939:0.705340:0.598939:0.005274:0.009164:0.010711:0.010664:0.005237:0.013139:0.009664:0.010664:0.013163:0.010664
KRAB/OTUB2:@0.803544:0.611738:0.871760:0.611738:0.871760:0.599725:0.803544:0.599725:0.007112:0.007283:0.007127:0.007084:0.004005:0.007868:0.006371:0.007868:0.007112:0.006385
 cells :@0.871864:0.619002:0.920578:0.619002:0.920578:0.598939:0.871864:0.598939:0.005274:0.009236:0.009759:0.004665:0.004761:0.009069:0.005951
in the G-phase (11.74% and 12.78%, respectively) compared to control groups (6.91% for HepG2  :@0.085519:0.642384:0.920574:0.642384:0.920574:0.622321:0.085519:0.622321:0.004761:0.010640:0.005427:0.005189:0.010640:0.009759:0.005356:0.013081:0.007982:0.010664:0.010711:0.009164:0.009188:0.009593:0.005427:0.006689:0.010568:0.010664:0.005284:0.010545:0.010664:0.016828:0.005427:0.009164:0.010497:0.010664:0.005451:0.010545:0.010664:0.005213:0.010664:0.010521:0.016828:0.005213:0.005475:0.006760:0.009640:0.009188:0.010664:0.009664:0.009236:0.005189:0.004665:0.009164:0.009640:0.004761:0.009212:0.006689:0.005427:0.009236:0.010664:0.015995:0.010664:0.009164:0.006760:0.009640:0.010664:0.005451:0.005189:0.010497:0.005427:0.009236:0.010664:0.010711:0.005022:0.006760:0.010664:0.004665:0.005427:0.010640:0.006760:0.010664:0.010687:0.010568:0.009236:0.005284:0.006689:0.010568:0.005213:0.010735:0.010545:0.016828:0.005403:0.005141:0.010664:0.006760:0.005379:0.013139:0.009664:0.010664:0.013163:0.010664:0.016506:0.005951
WT:@0.898233:0.635121:0.914723:0.635121:0.914723:0.623107:0.898233:0.623107:0.010120:0.006371
and 6.14% for HepG2:@0.085519:0.665767:0.266491:0.665767:0.266491:0.645704:0.085519:0.645704:0.009164:0.010711:0.010664:0.005665:0.010545:0.005213:0.010664:0.010664:0.016828:0.005522:0.005213:0.010735:0.006546:0.005713:0.012972:0.009759:0.010664:0.013068:0.010664
KRAB:@0.266581:0.658503:0.295187:0.658503:0.295187:0.646489:0.266581:0.646489:0.007112:0.007283:0.007127:0.007084
). Moreover, A similar pattern was observed in the S-phase, with increases :@0.295230:0.665767:0.920550:0.665767:0.920550:0.645704:0.295230:0.645704:0.006546:0.005213:0.005617:0.017043:0.010735:0.006760:0.009640:0.010545:0.009164:0.009640:0.006760:0.005213:0.005713:0.011901:0.005498:0.009236:0.004761:0.015900:0.004761:0.004642:0.009164:0.006665:0.005713:0.010664:0.009164:0.005118:0.005260:0.009759:0.006641:0.010711:0.005689:0.013377:0.009164:0.009093:0.005713:0.010664:0.010568:0.009236:0.009759:0.006641:0.009164:0.009640:0.010664:0.005736:0.004761:0.010497:0.005713:0.005189:0.010640:0.009759:0.005641:0.011892:0.007982:0.010664:0.010711:0.009164:0.009188:0.009593:0.005141:0.005713:0.013377:0.004761:0.005094:0.010711:0.005689:0.004761:0.010640:0.009236:0.006760:0.009664:0.009164:0.009188:0.009593:0.009236:0.005951
to 30.45% and 28.80% in HepG2:@0.085519:0.689183:0.377721:0.689183:0.377721:0.669120:0.085519:0.669120:0.005189:0.010664:0.008783:0.010664:0.010664:0.005213:0.010664:0.010664:0.016828:0.008831:0.009164:0.010711:0.010664:0.008640:0.010664:0.010664:0.005213:0.010664:0.010664:0.016828:0.008831:0.004761:0.010640:0.008807:0.013139:0.009664:0.010664:0.012996:0.010664
KRAB/OTUB1:@0.377898:0.681919:0.446114:0.681919:0.446114:0.669905:0.377898:0.669905:0.007112:0.007283:0.007127:0.007084:0.004005:0.007868:0.006371:0.007868:0.007112:0.006385
 and HepG2:@0.446171:0.689183:0.551456:0.689183:0.551456:0.669120:0.446171:0.669120:0.008837:0.009164:0.010711:0.010664:0.008783:0.012972:0.009759:0.010664:0.013068:0.010664
KRAB/OTUB2:@0.551549:0.681919:0.619764:0.681919:0.619764:0.669905:0.551549:0.669905:0.007112:0.007283:0.007127:0.007084:0.004005:0.007868:0.006371:0.007868:0.007112:0.006385
 respectively, compared to control :@0.619821:0.689183:0.920480:0.689183:0.920480:0.669120:0.619821:0.669120:0.008837:0.006760:0.009497:0.009236:0.010664:0.009759:0.009236:0.005189:0.004642:0.009164:0.009640:0.004761:0.009212:0.005213:0.008879:0.009236:0.010664:0.015995:0.010568:0.009164:0.006665:0.009759:0.010664:0.008783:0.005189:0.010664:0.008783:0.009236:0.010664:0.010711:0.005189:0.006665:0.010664:0.004761:0.005951
groups  (20.03%  for  HepG2   and  21.02%  for  HepG2:@0.085519:0.712565:0.597603:0.712565:0.597603:0.692502:0.085519:0.692502:0.010640:0.006760:0.010664:0.010687:0.010568:0.009236:0.005951:0.009997:0.006546:0.010664:0.010568:0.005213:0.010664:0.010664:0.016638:0.005951:0.009997:0.005141:0.010664:0.006760:0.005951:0.009950:0.013139:0.009664:0.010664:0.013163:0.010664:0.016685:0.005951:0.009870:0.009164:0.010711:0.010664:0.005951:0.009950:0.010545:0.010664:0.005213:0.010664:0.010664:0.016662:0.005951:0.009997:0.005141:0.010545:0.006760:0.005951:0.009926:0.013139:0.009664:0.010664:0.013163:0.010664
WT:@0.342835:0.705301:0.359326:0.705301:0.359326:0.693288:0.342835:0.693288:0.010120:0.006371
KRAB:@0.597729:0.705301:0.626335:0.705301:0.626335:0.693288:0.597729:0.693288:0.007112:0.007283:0.007127:0.007084
).  Meanwhile,  RT-PCR  analysis :@0.626378:0.712565:0.920480:0.712565:0.920480:0.692502:0.626378:0.692502:0.006546:0.005141:0.005951:0.009854:0.017043:0.009759:0.009164:0.010711:0.013377:0.010711:0.004642:0.004761:0.009640:0.005213:0.005951:0.010045:0.012163:0.010532:0.007839:0.011830:0.013163:0.012068:0.005951:0.009997:0.009164:0.010711:0.009069:0.004761:0.009212:0.009236:0.004761:0.009188:0.005951
demonstrates  a  significant  reduction  in  OTUB1  and  OTUB2  mRNA  levels  following  CRISPR :@0.085519:0.735947:0.920162:0.735947:0.920162:0.715885:0.085519:0.715885:0.010664:0.009759:0.015924:0.010664:0.010711:0.009236:0.005189:0.006641:0.009164:0.005094:0.009759:0.009188:0.005951:0.006712:0.008974:0.005951:0.006712:0.009236:0.004761:0.010640:0.010711:0.004523:0.005213:0.004761:0.009236:0.009164:0.010711:0.005094:0.005951:0.006712:0.006760:0.009640:0.010664:0.010687:0.009236:0.005189:0.004761:0.010664:0.010711:0.005951:0.006665:0.004761:0.010640:0.005951:0.006712:0.012972:0.010640:0.013139:0.011711:0.010664:0.005951:0.006736:0.009164:0.010711:0.010473:0.005951:0.006712:0.013139:0.010640:0.013139:0.011687:0.010664:0.005951:0.006593:0.015995:0.012092:0.013139:0.011901:0.005951:0.006760:0.004761:0.009640:0.009164:0.009640:0.004761:0.009188:0.005951:0.006736:0.005141:0.010545:0.004761:0.004642:0.010664:0.013377:0.004761:0.010711:0.010640:0.005951:0.006736:0.013163:0.012068:0.005332:0.011901:0.011830:0.012163:0.005951
knockdown. In HepG2:@0.085519:0.759229:0.268371:0.759229:0.268371:0.739166:0.085519:0.739166:0.009164:0.010711:0.010664:0.009236:0.009164:0.010664:0.010664:0.013377:0.010568:0.005213:0.005189:0.005332:0.010640:0.005141:0.012972:0.009759:0.010664:0.013068:0.010664
KRAB/OTUB1:@0.268434:0.751965:0.336650:0.751965:0.336650:0.739952:0.268434:0.739952:0.007112:0.007283:0.007127:0.007084:0.004005:0.007868:0.006400:0.007868:0.007084:0.006385
 cells, c-Myc expression decreased by 2.2-fold, TP53 by 2.8-fold, and :@0.336707:0.759229:0.920552:0.759229:0.920552:0.739166:0.336707:0.739166:0.005131:0.009236:0.009759:0.004523:0.004761:0.009188:0.005260:0.005141:0.009288:0.007839:0.016971:0.009212:0.009283:0.005141:0.009759:0.009474:0.010664:0.006760:0.009664:0.009188:0.009188:0.004761:0.010664:0.010711:0.005094:0.010664:0.009759:0.009236:0.006689:0.009759:0.009045:0.009236:0.009759:0.010664:0.005094:0.010545:0.009212:0.005189:0.010664:0.005213:0.010726:0.007839:0.005213:0.010735:0.004761:0.010664:0.005213:0.005022:0.010640:0.011830:0.010664:0.010664:0.004951:0.010664:0.009259:0.005141:0.010545:0.005213:0.010784:0.007839:0.005213:0.010735:0.004761:0.010497:0.005213:0.005189:0.009164:0.010711:0.010664:0.005951
HIF-:@0.085519:0.782611:0.122545:0.782611:0.122545:0.762549:0.085519:0.762549:0.013139:0.005237:0.010701:0.007950
1α and VEGF by 2.3:@0.122577:0.782611:0.292290:0.782611:0.292290:0.762549:0.122577:0.762549:0.010664:0.011235:0.006308:0.009164:0.010497:0.010664:0.006141:0.011901:0.010735:0.012972:0.010664:0.006284:0.010545:0.009212:0.006308:0.010545:0.005213:0.010664
-fold and 2.1-fold, respectively. Bcl-2, NF-:@0.292379:0.782611:0.648439:0.782611:0.648439:0.762549:0.292379:0.762549:0.007982:0.005213:0.010735:0.004761:0.010497:0.006236:0.009164:0.010711:0.010473:0.006236:0.010664:0.005213:0.010724:0.007839:0.005213:0.010735:0.004761:0.010664:0.005094:0.006236:0.006760:0.009640:0.009236:0.010664:0.009759:0.009236:0.004975:0.004761:0.009069:0.009759:0.004642:0.009212:0.005308:0.006236:0.011830:0.009236:0.004905:0.007982:0.010545:0.005213:0.006308:0.013139:0.010548:0.007950
κB, and CDH:@0.648470:0.782611:0.756796:0.782611:0.756796:0.762549:0.648470:0.762549:0.008974:0.011830:0.005213:0.006308:0.009164:0.010711:0.010473:0.006236:0.013163:0.013115:0.013139
-1 levels were also :@0.756794:0.782611:0.920374:0.782611:0.920374:0.762549:0.756794:0.762549:0.007982:0.010545:0.006236:0.004761:0.009640:0.009164:0.009640:0.004761:0.009188:0.006260:0.013377:0.009759:0.006641:0.009759:0.006189:0.009164:0.004665:0.009236:0.010664:0.005951
significantly reduced by 3.1-fold, 2.0-fold and 2.4-fold, respectively. HepG2:@0.085519:0.805994:0.715425:0.805994:0.715425:0.785931:0.085519:0.785931:0.009236:0.004761:0.010640:0.010711:0.004665:0.005213:0.004761:0.009236:0.009164:0.010711:0.005094:0.004761:0.009212:0.005832:0.006760:0.009640:0.010664:0.010568:0.009236:0.009759:0.010664:0.005832:0.010545:0.009212:0.005760:0.010664:0.005284:0.010657:0.007982:0.005141:0.010664:0.004761:0.010664:0.005118:0.005713:0.010664:0.005284:0.010550:0.007982:0.005141:0.010664:0.004761:0.010664:0.005832:0.009164:0.010711:0.010473:0.005855:0.010545:0.005213:0.010750:0.007887:0.005213:0.010735:0.004761:0.010664:0.005094:0.005855:0.006760:0.009640:0.009236:0.010664:0.009759:0.009236:0.005189:0.004642:0.009164:0.009640:0.004761:0.009212:0.005118:0.005855:0.013139:0.009664:0.010664:0.013163:0.010664
KRAB/OTUB2:@0.715460:0.798730:0.783547:0.798730:0.783547:0.786716:0.715460:0.786716:0.007112:0.007283:0.007127:0.007084:0.004005:0.007868:0.006371:0.007868:0.006984:0.006385
 showed similar :@0.783590:0.805994:0.920420:0.805994:0.920420:0.785931:0.783590:0.785931:0.005701:0.009236:0.010711:0.010664:0.013377:0.009759:0.010497:0.005713:0.009236:0.004761:0.015900:0.004761:0.004642:0.009164:0.006760:0.005951
but less pronounced reductions in gene expression compared to HepG2:@0.085519:0.829376:0.702152:0.829376:0.702152:0.809313:0.085519:0.809313:0.010664:0.010687:0.005189:0.007498:0.004761:0.009640:0.009236:0.009188:0.007474:0.010664:0.006593:0.010664:0.010711:0.010664:0.010687:0.010592:0.009236:0.009759:0.010664:0.007522:0.006760:0.009640:0.010664:0.010687:0.009236:0.005189:0.004761:0.010664:0.010521:0.009236:0.007522:0.004570:0.010711:0.007498:0.010640:0.009759:0.010711:0.009664:0.007522:0.009545:0.009521:0.010664:0.006760:0.009664:0.009188:0.009188:0.004570:0.010664:0.010711:0.007545:0.009117:0.010664:0.015995:0.010664:0.009164:0.006689:0.009759:0.010664:0.007498:0.005189:0.010497:0.007379:0.013139:0.009664:0.010664:0.013163:0.010664
KRAB/OTUB1:@0.702490:0.822112:0.770705:0.822112:0.770705:0.810099:0.702490:0.810099:0.007112:0.007283:0.007127:0.007084:0.004005:0.007868:0.006371:0.007868:0.007112:0.006385
. Based on these :@0.770620:0.829376:0.920505:0.829376:0.920505:0.809313:0.770620:0.809313:0.005213:0.007450:0.011830:0.009164:0.009188:0.009759:0.010664:0.007379:0.010664:0.010711:0.007545:0.005189:0.010640:0.009545:0.009236:0.009759:0.005951
findings, the increase in G-phase and S-phase percentages in PI staining indicates that knockdown :@0.085519:0.852759:0.920315:0.852759:0.920315:0.832696:0.085519:0.832696:0.005213:0.004761:0.010711:0.010664:0.004761:0.010711:0.010640:0.009093:0.005213:0.006308:0.005189:0.010640:0.009759:0.006189:0.004761:0.010640:0.009236:0.006593:0.009759:0.009045:0.009236:0.009759:0.006189:0.004761:0.010640:0.006236:0.013270:0.007982:0.010664:0.010711:0.009164:0.009188:0.009759:0.006070:0.009164:0.010711:0.010664:0.006212:0.012026:0.007839:0.010664:0.010711:0.009164:0.009188:0.009759:0.006212:0.010664:0.009759:0.006522:0.009236:0.009759:0.010711:0.005070:0.009164:0.010640:0.009759:0.009188:0.006260:0.004761:0.010640:0.006236:0.011830:0.005332:0.006189:0.009236:0.004999:0.009164:0.004665:0.010711:0.004689:0.010711:0.010640:0.006284:0.004761:0.010640:0.010664:0.004761:0.009236:0.009164:0.005094:0.009759:0.009188:0.006260:0.005189:0.010640:0.009164:0.005094:0.006236:0.009164:0.010711:0.010664:0.009236:0.009164:0.010664:0.010664:0.013377:0.010711:0.005951
of OTUB1 and OTUB2 leads to cell cycle arrest at the G2/S transition, hindering normal cell cycle :@0.085519:0.876040:0.920230:0.876040:0.920230:0.855977:0.085519:0.855977:0.010664:0.005284:0.007236:0.012972:0.010640:0.013139:0.011830:0.010568:0.007236:0.009164:0.010711:0.010664:0.007212:0.012972:0.010640:0.013139:0.011830:0.010664:0.007284:0.004761:0.009640:0.009164:0.010497:0.009236:0.007236:0.005189:0.010664:0.007069:0.009117:0.009759:0.004642:0.004761:0.007188:0.009236:0.009259:0.009236:0.004761:0.009664:0.007236:0.009164:0.006665:0.006760:0.009640:0.009236:0.005189:0.007590:0.009164:0.005094:0.007236:0.005189:0.010640:0.009759:0.007188:0.013163:0.010664:0.006689:0.011806:0.007236:0.005189:0.006641:0.009164:0.010711:0.009188:0.004761:0.005094:0.004761:0.010664:0.010711:0.005213:0.007117:0.010711:0.004689:0.010711:0.010664:0.009759:0.006641:0.004761:0.010640:0.010640:0.007284:0.010711:0.010521:0.006760:0.015900:0.009164:0.004665:0.007236:0.009236:0.009759:0.004665:0.004761:0.007188:0.009236:0.009259:0.009236:0.004761:0.009759:0.005951
progression.  Consequently,  this  arrest  results  in  reduced  cellular  proliferation,  suggesting  that :@0.085519:0.899422:0.920043:0.899422:0.920043:0.879360:0.085519:0.879360:0.010664:0.006760:0.010664:0.010640:0.006760:0.009664:0.009188:0.009188:0.004761:0.010664:0.010711:0.005213:0.005951:0.004451:0.013163:0.010497:0.010711:0.009188:0.009759:0.010664:0.010687:0.009759:0.010640:0.005189:0.004642:0.009212:0.005308:0.005951:0.004427:0.005189:0.010640:0.004761:0.009069:0.005951:0.004427:0.009164:0.006665:0.006760:0.009640:0.009236:0.005189:0.005951:0.004380:0.006760:0.009640:0.009236:0.010687:0.004761:0.005070:0.009236:0.005951:0.004427:0.004832:0.010711:0.005951:0.004404:0.006760:0.009640:0.010664:0.010687:0.009236:0.009759:0.010664:0.005951:0.004451:0.009236:0.009759:0.004665:0.004761:0.010687:0.004761:0.009164:0.006689:0.005951:0.004427:0.010664:0.006760:0.010664:0.004761:0.004642:0.005213:0.009759:0.006760:0.009045:0.005260:0.004761:0.010664:0.010711:0.005213:0.005951:0.004427:0.009236:0.010687:0.010545:0.010640:0.009759:0.009188:0.005189:0.004761:0.010640:0.010640:0.005951:0.004475:0.005189:0.010640:0.009164:0.004951:0.005951